5 Key Takeaways
-
1
AstraZeneca is establishing a commercial manufacturing and supply base for cell therapy in Shanghai.
-
2
The new facility will produce autologous CAR-T therapies for China and other Asian markets.
-
3
AstraZeneca will support the clinical trials of its BCMA/CD19 dual-target CAR-T candidate, AZD0120.
-
4
The AstraZeneca Gracell Cell Therapy Innovation Center will focus on early research and regulatory support.
-
5
AstraZeneca launched a collaboration program to connect Shanghai's biotech sector with UK research networks.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
